Oncologix Tech

Oncologix Tech FCF Conversion

Delisted·Sep 9, 2026

The FCF Conversion Rate (FCF/EBITDA) of Oncologix Tech (OCLG) as of Oct 28, 2026 is 1.06 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -18.60 % — a change of -105.69% (higher).

FCF Conversion

1.06 %

YoY

-105.69%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Oncologix Tech is 2017 1.06 % . FCF Conversion Rate (FCF/EBITDA) of Oncologix Tech was 2016 -18.60 % . It decreases by -105.69% higher compared to the previous year.

The Oncologix Tech FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2014
48.08 USD
Jan 1, 2015
14.09 USD
Jan 1, 2016
-18.60 USD
Jan 1, 2017
1.06 USD
The Oncologix Tech FCF Conversion history
YEARFCF ConversionYoY
1.06 %-105.69%
-18.60 %-232.01%
14.09 %-70.69%
48.08 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oncologix Tech Stock analysis

What does Oncologix Tech do? Oncologix Tech, Inc. generates revenue through the operation and manufacture of medical device products. The company collaborates with manufacturers and stakeholders in the United States and South Korea to execute agreements with partners, customers, vendors, and manufacturers. It reviews licenses and sublicense agreements with potential licensors and conducts research and due diligence on potential partners, joint-ventures, and acquisitions in the biotech industry. Oncologix Tech, Inc. seeks additional acquisitions of diagnostic and biotechnology opportunities to expand its portfolio. The firm's primary customers include partners, customers, vendors, and manufacturers within the medical device and biotech sectors. It targets opportunities in diagnostic and biotechnology fields through strategic acquisitions and partnerships. Oncologix Tech, Inc. focuses on executing agreements and conducting due diligence to secure new ventures in the biotech industry. Oncologix Tech, Inc. operates as a medical holding company with a focus on medical device products. It engages in reviewing licenses and sublicense agreements and conducts research on potential acquisitions. The company aims to expand its operations by acquiring diagnostic and biotechnology opportunities in the market. Oncologix Tech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oncologix Tech stock

FCF Conversion Rate (FCF/EBITDA) of Oncologix Tech is 1.06 % in 2017.

FCF Conversion Rate (FCF/EBITDA) of Oncologix Tech changed from -18.60 % to 1.06 %, representing a -105.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Oncologix Tech since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Oncologix Tech with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Oncologix Tech

All Key Metrics — Oncologix Tech